Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 4Phase 1/2 2

Status

Completed 4Withdrawn 2Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 4

Conditions

Neoplasms 1331Breast Neoplasms 688Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 437Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 366Lymphoma, Non-Hodgkin 356Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 267Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 254Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Hodgkin Disease 193Carcinoma, Renal Cell 193Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Glioma 172Burkitt Lymphoma 172

Interventions

filanesib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Bortezomib 2merphos 1ixazomib 1fludarabine phosphate 1carfilzomib 1Steroids 1Stem Cell Transplantation 1Sirolimus 1Proteasome Inhibitors 1Methotrexate 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Dexamethasone 1Cytarabine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × Leukemia, Plasma Cell × Clear all
NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

City of Hope Medical Center

Phase 1 Completed
18 enrolled
Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01372540 2019-07-16

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
76 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡